Targeting ZIP12

Presented at Genetics-inspired Therapeutics for PH by Rachel Gurrell, Apollo Therapeutics

Summary

Apollo Therapeutics is developing an innovative medicine for PH. Its first-in-class drug, APL-9796, targets ZIP12, a zinc ion transporter that plays a key role in PH. A phase 2 clinical trial, ViTAL-PH, is underway, building on favourable phase 1 safety and pharmacokinetic data.

Generated by AI, edited by PVRI